Periodic Reporting for period 1 - FibroFix (FibroFix™Cartilage, an innovative implant for cartilage repair and regeneration, introducing a new paradigm in osteoarthritis (OA) treatment.)
Reporting period: 2019-01-01 to 2019-04-30
Cartilage deterioration and injuries often lead to osteoarthritis (OA) – a long-term chronic disease resulting in bones rubbing together and creating pain, stiffness and severe disability. Knee cartilage injuries are very common and almost half of them go on to develop OA, which is second only to heart disease as a cause of work disability. Orthox has developed and plans to bring to market FibroFix Cartilage - a product developed to treat damage to the articular cartilage in the knee, including degeneration and OA.
During the feasibility assessment, Orthox has completed a full analysis of the technical and business potential of their FibroFix Cartilage. Throughout the project, Orthox has greatly expanded their knowledge regarding the clinical validation and regulatyory approval required for the European market launch. Orthox also identified all key stakeholders needed for commercialisation.
To prevent total knee replacement, many patients who suffer injury to the meniscus or knee cartilage are advised to limit their activity or risk deterioration of the joint. Orthox offers an alternative - strong, resilient, natural implants capable of restoring knee function while allowing the body’s own cells to grow through and integrate with the device. It is expected that this solution will allow patients to return to a fully active, pain-free lifestyle.